HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elizabeth Arden Unveils Premium-Priced Prevage Anti-Aging Treatment

This article was originally published in The Rose Sheet

Executive Summary

Elizabeth Arden is positioning its Prevage Anti-Aging Treatment as a revolutionary formula that "alters the chain reaction that can result in older looking skin," according to the firm

You may also be interested in...



Arden Net Sales Advance 7% In Q2 On Prevage, Fantasy Launches

Elizabeth Arden will emphasize Internet banner and print advertising in support of its Prevage anti-aging product, while stepping back from mediums like outdoor advertising, CEO Scott Beattie said during a Feb. 2 second quarter earnings call

Arden Net Sales Advance 7% In Q2 On Prevage, Fantasy Launches

Elizabeth Arden will emphasize Internet banner and print advertising in support of its Prevage anti-aging product, while stepping back from mediums like outdoor advertising, CEO Scott Beattie said during a Feb. 2 second quarter earnings call

Sales & Earnings In Brief

Elizabeth Arden: Prevage anti-aging treatment launch will be supported with print ads in 21 magazines over the next eight weeks, in addition to radio spots and Internet banners, company announces during Nov. 3 Q1 call. Prevage will be distributed in department and specialty stores including Saks Fifth Avenue, Nordstrom, Bloomingdale's, Henri Bendel and Bergdorf Goodman. The firm unveiled the line in September (1"The Rose Sheet" Aug. 15, 2005, p. 4). Arden's net sales increased 7.2% to $227.4 mil. for the first quarter (ended Sept. 30). Net income was $1.9 mil., excluding stock compensation expense, versus $4.8 mil. in the same period last year, due in part to weak consumer spending in Western Europe, Arden said. The firm has lowered full fiscal 2006 guidance, with sales expected to increase 6.5%-8% to $980 mil.-$995 mil., versus earlier expectations of $1 bil. - $1.02 bil. Earnings per diluted share for the year are anticipated to increase to $1.33-$1.39, excluding stock compensation expense...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel